More recently, PARK2 somatic mutations have been associated with different types of cancer (69), suggesting that germline mutations in PARK2 cause PD and somatic mutations contribute to cancer (for a review see Plun-Favreau et al.) (70). This evidence concerns the gene PRKN and Parkinson disease.